H.R. 5668 · 116th Congress
Making Objective Drug Evidence Revisions for New Labeling Act of 2020
- Stage
- Passed a chamber
- Sponsor
- Doris Matsui
- Introduced
- 2020-01-24
- Latest action
- 2020-11-18 · Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Congressional oversight
Health
Prescription drugs
Drug safety, medical device, and laboratory regulation